XKRX200670
Market cap301mUSD
Dec 24, Last price
44,350.00KRW
1D
-3.38%
1Q
22.51%
Jan 2017
48.52%
IPO
53.12%
Name
Humedix Co Ltd
Chart & Performance
P/E
17.72
P/S
2.89
EPS
2,503.06
Div Yield, %
1.61%
Shrs. gr., 5y
0.66%
Rev. gr., 5y
18.62%
Revenues
152.27b
+23.63%
Net income
24.82b
+17.71%
CFO
30.89b
-19.05%
Dividend
Jun 27, 2024250 KRW/sh
Earnings
May 08, 2025
Profile
Humedix Co., Ltd., a healthcare company, researches, develops, manufactures, and sells various pharmaceutical products in South Korea. It offers over-the-counter drugs, prescription medicines, active pharmaceutical ingredients, medical devices, cosmetic products, and functional synthetic materials, as well as health functional foods. The company was formerly known as HVLS Co., Ltd. and changed its name to Humedix Co., Ltd. in 2010. The company was founded in 2002 and is headquartered in Anyang-si, South Korea.
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 152,273,809 23.63% | 123,172,790 10.97% | 110,992,354 12.70% | ||||||
Cost of revenue | 104,414,400 | 89,152,893 | 87,467,492 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | 47,859,409 | 34,019,897 | 23,524,862 | ||||||
NOPBT Margin | 31.43% | 27.62% | 21.20% | ||||||
Operating Taxes | 7,589,537 | 7,835,213 | 1,287,588 | ||||||
Tax Rate | 15.86% | 23.03% | 5.47% | ||||||
NOPAT | 40,269,871 | 26,184,684 | 22,237,274 | ||||||
Net income | 24,820,705 17.71% | 21,086,066 132.62% | 9,064,624 -39.91% | ||||||
Dividends | (7,079,053) | (3,760,468) | (3,762,965) | ||||||
Dividend yield | 2.12% | 1.46% | 1.67% | ||||||
Proceeds from repurchase of equity | 531,978 | (5,975,201) | (23,063) | ||||||
BB yield | -0.16% | 2.33% | 0.01% | ||||||
| Debt | |||||||||
Debt current | 946,400 | 33,202,353 | 810,371 | ||||||
Long-term debt | 4,457,059 | 4,874,180 | 31,922,821 | ||||||
Deferred revenue | 348,659 | 1,900,569 | |||||||
Other long-term liabilities | 556,315 | 492,253 | 2,812,445 | ||||||
Net debt | (106,191,332) | (80,314,625) | (46,264,698) | ||||||
| Cash flow | |||||||||
Cash from operating activities | 30,885,208 | 38,152,027 | 19,184,530 | ||||||
CAPEX | (9,029,953) | (7,280,306) | (14,743,262) | ||||||
Cash from investing activities | (15,473,951) | 53,955,719 | (50,354,411) | ||||||
Cash from financing activities | (25,808,378) | (10,623,928) | 20,063,794 | ||||||
FCF | 7,212,881 | 66,460,232 | 17,513,299 | ||||||
| Balance | |||||||||
Cash | 80,247,345 | 90,715,939 | 54,353,436 | ||||||
Long term investments | 31,347,446 | 27,675,220 | 24,644,454 | ||||||
Excess cash | 103,981,101 | 112,232,519 | 73,448,272 | ||||||
Stockholders' equity | 103,415,116 | 77,098,015 | 74,756,268 | ||||||
Invested Capital | 97,905,985 | 90,556,580 | 102,601,525 | ||||||
ROIC | 42.74% | 27.11% | 22.01% | ||||||
ROCE | 23.77% | 20.29% | 13.20% | ||||||
| EV | |||||||||
Common stock shares outstanding | 9,880 | 9,274 | 9,403 | ||||||
Price | 33,750.00 21.84% | 27,700.00 15.66% | 23,950.00 0.84% | ||||||
Market cap | 333,464,276 29.81% | 256,876,975 14.06% | 225,208,101 -0.23% | ||||||
EV | 227,272,944 | 176,562,350 | 194,905,743 | ||||||
EBITDA | 59,136,882 | 45,512,743 | 35,798,739 | ||||||
EV/EBITDA | 3.84 | 3.88 | 5.44 | ||||||
Interest | 1,446,106 | 3,165,249 | 2,234,621 | ||||||
Interest/NOPBT | 3.02% | 9.30% | 9.50% | ||||||